

P.O. Box 8738, Dayton, OH 45401-8738 | www.CareSource.com

Re: Summary of Formulary Changes Effective May 1, 2021

Dear Health Partner,

We are dedicated to partnering with you in the most effective way to manage our members' care. CareSource routinely reviews medications available on the Preferred Drug List (PDL). We encourage you to actively work with your CareSource patients in advance of the effective date above to ensure a smooth transition.

THE FOLLOWING MEDICATIONS WILL BE NON-PREFERRED ON THE PDL EFFECTIVE MAY 1, 2021

Brand Name	Generic Name	Strength(s)	Notes
Soliris	Eculizumab	300 mg/30 mL	Current utilizers will be
			grandfathered.

THE FOLLOWING MEDICATIONS WILL BE PREFERRED ON THE PDL EFFECTIVE MAY 1, 2021.

Brand Name	Generic Name	Strength(s)	Notes
Enspryng	Satralizumab-	120 mg/mL	Prior authorization required.
	mwge		

THE FOLLOWING MEDICATIONS HAVE A CHANGE IN STATUS EFFECTIVE MAY 1, 2021.

Brand Name	Generic Name	Strength(s)	Notes
Tre le gy Ellipta	Fluticasone furoate,	100 mcg/62.5	Step therapy required.
	umeclidinium,	mcg/25 mcg,	
	vilanterol	200 mcg/62.5	
		mcg/25 mcg	

What you should know

We know patient care is of the utmost importance to you. We are notifying our members of this change to help ensure their treatment plan is maintained. We have asked our members to contact their prescriber if they have questions.

Additional Resources

For the most up-to-date information, please utilize the <u>formulary search tools</u> online. To access the complete formulary, visit the Provider Pharmacy pages at CareSource.com. You may find your patient's plan formulary by clicking on:

- Your patient's CareSource plan
- Tools & Resources
- Drug Formulary

We recognize each patient is unique and we appreciate your partnership in making this a successful transition. We are here to help you with any questions. Call the CareSource RX Innovations Department at 1-844-607-2829. The Department is open Monday through Friday, 8 a.m. to 5 p.m. Thank you for being a CareSource health partner.

IN-P-0224a; First Use: 3/14/2019 OMPP Approved: 3/7/2019